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Background: This study was conducted to investigate awareness of clinical trials (CTs) including perceptions of
favorable feelings about, necessity for, and safety of CTs, the ultimate beneficiary of CTs and the factors associated
with willingness to participate in CTs among the general population in South Korea.
Methods: A cross sectional survey study was conducted in a randomly selected national sample of 1,515 Korean.
Results: Perception toward CTs was measured using a scale from 0 (strongly disagree) to 10 (strongly agree).
Respondents readily understood the necessity for CTs (M = 7.27, SD = 2.15); had moderately favorable feelings
(M = 5.32, SD = 2.31) toward CTs and felt that these CTs were moderately safe (M = 4.71, SD = 1.90). Twenty-five
percent of the respondents answered that they would be willing to participate in a CT in the future. Perception
of the ultimate benefits of CTs, awareness, favorable feelings, safety, and necessity regarding CTs were identified
as significant predictors of willingness to participate in CTs.
Conclusion: An awareness of CTs and the perceptions toward CTs were associated with general public willingness
to participate in a CT. Findings from this study can be used in planning outreach and recruitment strategies, and to
understand the predictors of CT participation.
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South Korea has become one of the most active countries
performing industry-sponsored trials under the trend of
globalization [1]. Participant recruitment is one of the
most important steps that determine the success of a trial
[2-4]. The perception and attitude of participants toward
clinical trials (CTs) are a key determinant in successful
recruitment and retention. One systematic review reported
that the most common factor that motivates people to par-
ticipate in CTs is altruism [5]. However, many previous
studies on this issue have been conducted in Western
countries or with patients with specific ethnicities, such as
Caucasians, African-Americans, or Latinos [6-10]. Due to
the social and cultural differences between Eastern and
Western countries, it is difficult to directly generalize
outcomes obtained in the West to the people of Asia,
including Koreans.* Correspondence: awesomeprof@jbnu.ac.kr
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unless otherwise stated.Over the past decade, the number of CTs in Asian
countries has increased rapidly due to important evidence
based on ethnic diversity and cost-effectiveness in clinical
trials. However, less is known about CT participation in
Asians [11], and studies that included large samples
from the general Asian public remain quite limited.
Therefore, the investigation of what the Korean people
know and how they feel about CTs is the first step toward
implementing these outcomes to improve participation in
clinical research in Asian countries and caring present
and future participants.
We conducted this study to identify the public awareness
of CTs and the factors affecting willingness to participate in
clinical trials in Korea.Methods
Study design and participants
This was a descriptive study using a face-to-face ques-
tionnaire survey method. The target population was the
general South Korean population aged 19 years and over.
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participants of interest. The sampling and data collection
process in this study was conducted in cooperation with
Gallup Korea, which is a specialized marketing research
company in Korea, from 7–24 November 2008. The
sampling domain was subdivided into ‘strata’ by the size
of municipalities. Regions were divided by metropolitan
cities (population more than 1,000,000), cities (population
between 50,000 and 1,000,000), and rural area (population
less than 50,000) based on the Local Autonomy Law of
Korea. Metropolitan cities and cities were considered
urban. A total of 15 strata were defined (seven metropol-
itan cities and eight provinces including 40 cities and 10
rural areas). The number of surveys in each stratum was
calculated in proportion to the distribution of the house-
hold and population of the ‘stratum’ in the area based on
2007 Korea statistics of resident registration, the latest
data available. Strata were narrowed to 102 smaller units
of administrative districts in urban areas and rural areas
such as ‘dong’ for urban areas and ‘eup or myon’ for rural
area. The principal investigator (PI) trained the inter-
viewers about the study purpose and procedure before
data collection and monitored the data collection process
throughout the study period. The sampling error for this
study was ±3% at a 95% confidence interval (CI). Ethical
approval was obtained from the Institutional Review
Board of Severance Hospital of Yonsei University Health
System (No. 4-2008-0415).
Instruments
The investigators developed a questionnaire in collabor-
ation with clinical researchers and clinical research coor-
dinators. The questionnaire included basic demographic
information and experience with CT participation; aware-
ness of CTs and source of information of CTs; perceptions
on favorable feelings about, necessity for, and safety of
CTs; perception of the ultimate beneficiary of CTs; and
willingness to participate in CTs.
Awareness of CTs was measured by asking “Have you
ever heard about CTs?” Participants were given the
following seven choices regarding the sources from
which they obtained information about CTs: relatives or
friends; mass media, such as TV or radio, newspaper,
internet; advertisements for recruitment in hospitals;
promotional material; and medical staff. Before assessing
the general perception of CTs, interviewers explained
CTs to participants using a standardized definition of
CTs (any trial or investigation in human subjects to be
intended to verify the effects of an investigational drugs
or treatments with the object of ascertaining its safety
and/or efficacy). Three questions were asked concerning
the participants’ perceptions of CTs: favorable feeling,
necessity and safety. Each question was measured using
an 11-point Likert-type scale. Scores of 0–3, 4–6, and 7–10 were assigned to correspond with low-level, moderate-
level, and high-level classes, respectively. We assessed
any previous experience with CTs by asking “Have you
ever participated in CTs?” The question of perception
on the ultimate beneficiary of CTs had four possible
answer choices: pharmaceutical companies, hospitals or
physicians, patients, and advances in medical science or
national economic benefits. The question about willing-
ness to participate in CTs was measured dichotomously
by asking “What is the likelihood of your taking part in a
clinical trial in the future?” and “If your family member
had a disease and needed a new treatment or drug, would
you be willing to participate in a clinical trial?” A pilot test
of the questionnaire was performed to determine question
clarity and average time required for completion.
Statistical analyses
Descriptive statistics of respondent demographics, aware-
ness of CTs, perceptions of CTs, and willingness to par-
ticipate in CTs were analyzed. Associations among the
variables were evaluated by χ2 test, independent t-test, or
one-way ANOVA. Multivariate analysis was also conducted
by logistic regression. Adjusted odds ratios (ORs) and 95%
confidence interval (CI) were calculated by logistic regres-
sion methods to examine the effects of the awareness,
experience, and perception variables on willingness to
participate in CT. All analyses were performed using
the Statistical Package for the Social Sciences (SPSS) for
Windows, version 15.0 at a level of significance of p < .05.
Results
Demographic data of the 1,515 respondents are shown
in Table 1. Males and females were evenly represented
in this study (49.7% vs. 50.3%). Overall, 47.5% of the
respondents lived in metropolitan cities, 41.1% in small
cities, and 11.4% in rural areas. Only 2.1% of the partici-
pants had previously participated in CTs.
Awareness of CTs
When asked whether they had ever heard about CTs,
75.1% of respondents answered in the affirmative. Aware-
ness of clinical trials was significantly more prevalent
among male respondents, 30–49 years of age, who were
more highly educated and were residents of metropolitan
cities or rural areas (Table 2). The five most cited methods
from which CT information had been obtained (in
descending order) were mass media, such as TV and radio
(86%) and newspapers (24.6%), relatives or friends (8.8%),
the internet (7.5%), and advertisements in hospitals (4.2%).
Perceptions toward CTs
The mean scores for the three categories of favorable feel-
ing, safety, and necessity of CTs were 5.32 (SD = 2.31),
4.71 (SD = 1.90) and 7.27 (SD = 2.15), respectively. The
Table 2 Respondent awareness of clinical trials (N = 1,515)
Variable Yes
n (%)
χ2 p
Gender Male 594 (78.9) 11.377 .001
Female 544 (71.4)
Age (years) 19-29 215 (72.9) 85.792 <.001
30s 306 (81.6)
40s 348 (84.7)
50s 173 (69.2)
≥60 96 (52.2)
Education level ≤ High school 692 (72.2) 11.576 .001
≥ College 446 (80.1)
Region Metropolitan cities 565 (78.5) 13.100 .001
Cities 438 (70.3)
Rural area 135 (78.5)
Household income
(1,000 won/month)
<2,000 208 (59.9) 73.604 <.001
2,000-2,999 337 (83.0)
3,000-3,999 284 (80.5)
≥4,000 301 (77.2)
Living style Alone 48 (60.8) 9.115 .003
With family 1087 (75.1)
Table 1 General characteristics of respondents (N = 1,515)
Variable Category n %
Gender Male 753 49.7
Female 762 50.3
Age (years) 19-29 295 19.5
30s 375 24.8
40s 411 27.1
50s 250 16.5
≥60 184 12.1
Education level ≤ High school 958 63.2
≥ College 557 36.8
Region Metropolitan cities 720 47.5
Cities 623 41.1
Rural area 172 11.4
Household income (1000 won/month) <2,000 347 22.9
2,000-2,999 406 26.8
3,000-3,999 353 23.3
≥4,000 390 25.7
Don’t know 19 1.3
Living style Alone 79 5.2
With family 1433 94.8
Experience in a clinical trial No 1114 97.9
Yes 24 2.1
Missing data were not included.
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cantly lower than those of adults in their 30s, 40s, and 50s
(p < .001). Significant differences were found between
residents of metropolitan cities and those of other areas
(p < .001). Awareness of CTs was significantly associated
with favorable feeling, safety, and necessity of CTs. Those
who were aware of CTs had significantly higher favorable
feeling (p < .001), necessity (p < .001), and safety (p < .001)
perceptions toward CTs than the respondents who were
not (Table 3). A question regarding the ultimate outcome
of CTs indicated that 45% of respondents believed that
patients received benefit from CTs. This was followed by
pharmaceutical companies (30.6%), advances in medical
science (15.6%), and hospitals or physicians (9.0%).
Willingness to participate in CTs
We asked “What is the likelihood of your taking part in
a clinical trial in the future?”, 25% of respondents indi-
cated that they would be willing to participate in a CT.
When asked, “if your family member had a disease and
needed a new treatment or drug, would you be willing
to participate in a clinical trial?”, 48.6% of respondents
indicated their willingness to participate.
Table 4 shows the associations between variables and
willingness to participate in CTs in the univariate ana-
lysis. Six variables (perception on ultimate beneficiary of
CTs, experience, awareness, favorable feeling, safety, and
necessity) showed a significant association with willing-
ness to participate in CTs according to the Chi-squared
test (p < .001, p = .042, p < .001, p < .001, p < .001, and
p < .001, respectively). Other factors, including gender,
age, educational level, resident area, household income, or
living style, were not significantly associated with willing-
ness to participate in CTs.
Multiple logistic regression was further conducted on
the following six variables: perception of the ultimate bene-
ficiary of CTs, experience, awareness, favorable feeling,
safety, and necessity. All variables except for experience
with CTs were significant predictors (Table 5). In multi-
variate analysis, the respondents who believed that the
ultimate beneficiary of CTs was the patient or advances in
medical science (rather than a pharmaceutical company)
were more likely to participate in CTs (OR = 1.59, 95% CI
1.11–2.27, p = .011; OR = 1.60, 95% CI 1.02–2.52, p = .043,
respectively). Respondents who were aware of CTs also
were more willing to participate in CTs (OR = 1.82, 95%
CI 1.35–2.45, p < .001). Participants with higher levels of
favorable feeling, safety, and necessity for CTs were also
more likely to be willing to participate. Those who were
agreeable to participating in CTs had more favorable feel-
ings toward CTs (moderate: OR = 1.70, 95% CI 1.00–2.89,
p = .051; and high: OR = 3.25, 95% CI 1.91–5.54, p < .001),
reported higher beliefs of CT safety (moderate: OR = 2.63,
95% CI 1.63–4.24, p < .001; and high: OR = 10.88, 95% CI
Table 3 Respondent perception of clinical trials (N = 1,515)
Variable Category Favorable feeling Safety Necessity
M (SD) t or F p M (SD) t or F p M (SD) t or F p
Gender Male 5.40 (2.34) 1.378 .168 4.70 (1.93) −0.292 .770 7.36 (2.18) 1.677 .094
Female 5.24 (2.28) 4.72 (1.86) 7.17 (2.12)
Age (years) 19 ~ 29 5.00 (2.23) 20.752 .004 4.57 (1.90) 5.984 .156 6.77 (2.16)a 26.135 <.001
30s 5.11 (2.30) 4.64 (1.85) 7.28 (2.30)b a < b
40s 5.53 (2.22) 4.90 (1.81) 7.49 (1.99)b
50s 5.54 (2.55) 4.74 (1.95) 7.46 (2.20)b
≥60 5.49 (2.24) 4.61 (2.10) 7.26 (1.99)
Education ≤High School 5.37 (2.30) 6.427 .272 4.73 (1.87) 1.205 .563 7.29 (2.14) 1.113 .624
≥ College 5.23 (2.32) 4.67 (1.95) 7.23 (2.18)
Region Large city 5.44 (2.24) 13.682 .077 4.82 (1.97) 9.319 .075 7.00 (2.20)a 53.033 <.001
Small city 5.16 (2.42) 4.58 (1.86) 7.46 (2.16)b a < b
Rural area 5.37 (2.16) 4.73 (1.70) 7.68 (1.75)b
Household income <2,000 5.24 (2.41) 8.345 .181 4.69 (1.88) 0.957 .901 7.02 (2.30) 16.105 .007
2,000-2,999 5.43 (2.20) 4.76 (1.85) 7.37 (1.91)
3,000-3,999 5.14 (2.24) 4.65 (2.00) 7.13 (2.24)
≥4,000 5.39 (2.41) 4.72 (1.89) 7.44 (2.16)
Living style Alone 5.39 (2.30) 0.301 .763 4.66 (1.69) −0.234 .815 7.23 (2.07) −0.153 .879
With family 5.31 (2.31) 4.71 (1.91) 7.27 (2.16)
Awareness of CT No 4.66 (2.33) −6.469 <.001 4.21 (1.86) −5.910 <.001 6.66 (2.39) −5.901 <.001
Yes 5.54 (2.26) 4.87 (1.89) 7.47 (2.03)
Experience in CT No 5.51 (2.26) −2.938 .003 4.88 (1.87) 0.436 .663 7.47 (2.02) 0.834 .404
Yes 6.88 (2.17) 4.71 (2.44) 7.13 (2.19)
a < b in post doc test.
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sary (moderate: OR = 3.40, 95% CI 0.69-16.78, p = .133;
and high: OR = 4.99, 95% CI 1.05–23.69, p = .043).
Discussion
The current study provides the first nationwide population-
based data of Koreans’ awareness of CTs and willingness
to participate in CTs. Awareness is the first step to the
successful implementation of CTs. The main finding of
this study was that willingness to participate in CTs in the
future was affected by respondent awareness and percep-
tion of CTs, such as favorable feeling, safety and necessity
of CTs.
The willingness to participate in CTs was significantly
higher among respondents with awareness of CTs than
it was in those who did not know about CTs. This result
is consistent with previous reports [6,11]. Comis et al.
[6] reported that respondents who had a high level of
understanding of CTs were more likely to have a positive
attitude toward participation than those with lower
levels of understanding. These results show that the
understanding of CTs is a cornerstone to the successful
recruitment and retention of trial participants. Most ofthe respondents in the present study (86%) had a gen-
eral idea about CTs from the mass media, such as TV
or radio. Therefore, mass media campaigns could be a
good strategy to increase the awareness of CTs, which
was also suggested by previous researchers [11].
A strong association between positive perception (espe-
cially for safety and favorable feeling) and willingness to
participate in CTs was found in this study. Participants
who perceived CTs to be highly safe were approximately
11 times more likely to be willing to participate in CTs
compared to those who were less sure of the safety. These
results suggest that a fear of adverse effects from the drug
or treatment is one of the most prominent barriers to
participation in CTs. The issue of safety in CTs was also
addressed in previous studies. Concern about drug side
effects was the most important cause of unwillingness
to participate in CTs [12], and recruitment remained a
challenge for participants worried about being assigned
to a less effective treatment [13]. Studies have also shown
that a previous bad experience or mistrust in the process
of obtaining informed consent or establishing a trusting
relationship with their doctors is also a barrier to partici-
pation in CTs [12,14]. A reduction in trust as a result of
Table 4 Respondent willingness to participate in clinical trials (N = 1,515)
Variable n (%) x2 p
Gender Male 204/753 (27.1) 3.665 .056a
Female 174/762 (22.8)
Age (years) 19~29 64/295 (21.7) 1.205 .272b
30’s 89/375 (23.7)
40’s 114/411 (27.7)
50’s 68/250 (27.2)
≥60 43/184 (23.4)
Education ≤ High school 240/958 (25.1) 0.014 .905a
≥ College 138/557 (24.8)
Resident areas Large city 190/720 (26.4) 3.161 .075b
Small city 155/623 (24.9)
Rural area 33/172 (19.2)
Household income <2,000 89/347 (25.6) 0.213 .644b
(1,000 won/month) 2,000 ∼ 2,999 109/406 (26.8)
3,000 ∼ 3,999 79/353 (22.4)
≥4,000 97/390 (24.9)
Living style Alone 26/76 (32.9) 2.834 .092a
With family 351/1433 (24.5)
Perception on ultimate beneficiary of CT Pharmaceutical company 85/463 (18.4) 18.473 <.001a
Hospital or physician 30/136 (22.1)
Patients 195/678 (28.8)
Advances in medicine 68/236 (28.8)
Experience of CT participation No 302/1114 (27.1) 4.131 .042a
Yes 11/24 (45.8)
Awareness of CT No 65/377 (17.2) 15.929 <.001a
Yes 313/1138 (27.5)
Favorable feeling toward CT Low 25/327 (7.6) 157.311 <.001b
Moderate 128/680 (18.8)
High 225/508 (44.3)
Safety toward CT Low 28/410 (6.8) 240.003 <.001b
Moderate 189/848 (22.3)
High 161/257 (62.6)
Necessity toward CT Low 2/87 (2.3) 63.434 <.001b
Moderate 52/366 (14.2)
High 324/1062 (30.5)
aPearson x2. bLinear-by-linear association.
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ately misleading CT that harmed some participants, has
decreased the willingness of African Americans to partici-
pate in a medical research study [15]. Therefore, effective
communication between participants and researchers is
crucial to establish trust and facilitate CT participation.
Researchers must make more efforts and dedicate time
to offer balanced information between benefits and
risks, and to explain the expected adverse reactions ordisadvantages to participants, as well as to address the
responses that would be taken in such situations. Most of
all, adherence to research ethics, which provide investiga-
tor guidance for human rights protection in order to
maximize research benefits, reduce risks and assure dis-
tributive justice to CT participants during trials, is the
most important factor in the success of a CT [9]. There-
fore, nurses need to be well-informed of related ethics and
guidelines, as existential advocates for clients.
Table 5 Factors associated with willingness to participate in clinical trials (N = 1,515)
Variable Adjusted ORa 95% CI p
Perception of ultimate beneficiary of CT Pharmaceutical companyb 1
Hospital or physician 1.562 0.84-2.91 .161
Patients 1.589 1.11-2.27 .011
Advances in medicine 1.600 1.02-2.52 .043
Experience with CT Nob 1
Yes 2.046 0.79-5.34 .143
Awareness of CT Nob 1
Yes 1.821 1.35-2.45 <.001
Favorable feeling toward CT Lowb 1
Moderate 1.698 1.00-2.89 .051
High 3.254 1.91-5.54 <.001
Safety of CT Lowb 1
Moderate 2.631 1.63-4.24 <.001
High 10.877 6.43-18.41 <.001
Necessity of CT Lowb 1
Moderate 3.40 0.69-16.78 .133
High 4.99 1.05-23.69 .043
aAdjusted for other significant factors; obtained by multiple logistic regression analysis.
bReference group.
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clinical trials and perceived the high necessity of CTs,
only 25% of participants reported willingness to partici-
pate in CTs in the future. These results are very similar to
those of a study in Germany that reported that while
89.5% of survey participants judged CTs to be important,
only 25% expressed willingness to participate [16]. In their
study, the willingness to participate was significantly
higher in people who thought CTs were important, had
knowledge about CTs and had previously participated in
CTs. In our survey, 25% of the respondents were willing
to participate, which was somewhat lower than the results
of other previous results, and may be an indication of
differences in race, ethnicity or culture in the study
participants [6,8,9]. A survey of 1,022 adults in England
reported that the majority of respondents were willing
to participate in CTs for major illnesses (63%) and cancer
(65%) [17]. However, the lower rate of willingness to
participate in our study increased about two-fold (48.6%)
when participants were given a scenario in which their
family member had a disease and needed a new treatment
or drug. This finding may reflect that participation does
not only depend on the perception or attitude of respon-
dents, but also on other factors. Actual CT participation
may be different from reported actions, especially when
people are confronted with a family member’s diagnosis
of illness. Various factors that were not measured in
this study can affect actual participation rates, such as
participant health status, comorbidities, availability oftreatment options, economic benefit, participant burden,
and inconvenience.
The likelihood of the general population to participate
in CTs was not different by age, educational level or
socioeconomic status in this study. However, residents
of metropolitan cities, those who were male, and people
in their 40s and 50s were more likely to participate in
CTs. These results are interesting because a previous
study indicated that a busy lifestyle, lack of time due to
work and the existence of family were some barriers to
participation in CTs [12]. In our study, younger adults
were significantly more likely to have negative views
on the necessity of CTs than were middle-aged adults,
and younger people also had a negative tendency to
participate in CTs. These results were different from
those of a previous study [6], which reported that younger
adults are more likely to have a positive perspective on
participation in CTs than are older adults. However,
our findings agreed with those of another study [18]. A
literature review found altruism to be a major factor of
CT participation among the general population [5]; weak
altruism, which is an unwillingness to accept more than
minimal personal risk for the sake of communal benefit,
may hinder participation [19]. The younger generation
in Asia grew up in an era of a conspicuous trend
toward nuclear families, a rapidly developing economy
and likelihood for adapting Western culture and values;
these factors might have different effects on public altru-
ism compared to those of the older generation. However,
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altruism and participation intention were also identified
in the present study. Respondents who believed that
the ultimate beneficiaries of CTs were the patients or
advances in medical science rather than pharmaceutical
companies were more likely to participate in CTs.
Previous experience with CT participation was associated
with the willingness to participate in CTs in the univariate
analysis, but this prior experience did not affect the
likelihood of participating in CTs in this study. About
2% of our respondents had previously taken part in CTs.
A very small fraction of previous CT participants among
the respondents may mask a true difference in willingness
in this study. Ohmann and Deimling [16] reported that
previous participation in a CT was significantly associated
with positive trial participation intention. Therefore, the
strategy to share previous participant experience regarding
the processes involved, the process of informed consent
and individual or social benefits as outcomes of CTs with
the general public through the mass media could have an
impact on CT awareness and attitude toward CTs.
Recently, Korea Food and Drug Administration (KFDA)
had announced the roadmap to foster the growth of CTs
toward a leading country in participating in biopharma-
ceutical CTs including a strategy to enhance communica-
tion to the general public on CTs. As a part of this, the
Korea National Enterprise for CTs (KoNECT) distributed
a 4 minute movie enhancing awareness of and necessity
for CTs to any institution with the educational purpose
for patients or the general public. We expect that the mass
media campaign to improve public awareness and trust
on CTs would be carried out in the near future in Korea.
However, a mass media campaign itself might not guaran-
tee the increment of patient willingness to participate in
and accrual to CTs [20]. The higher enrollment rates
could be achieved through positively changing patients
and their family’s attitude toward participation in CTs
using more targeted educational approaches [21].
Strengths of this study included the use of a sufficiently
large probability sample to represent a nationwide popula-
tion and to compare the differences among geographical
regional area within 5% of the sampling error. However,
this study had several limitations. First, willingness to
participate in CTs does not reflect actual enrollment: only
a behavioral intention. Respondents may be more likely
to answer positively about willingness to participate
due to a tendency to exhibit pleasing behavior. Future
studies should examine the extent to which behavioral
intention predicts actual enrollment in CTs and also the
circumstances under which participation does not occur.
Second, the willingness to participate in CTs depends on
factors other than the attitude of the patient. Therefore,
various factors which were not measured in this study can
affect the actual participation rates in CTs. Nonetheless,findings from this study can be useful in understanding
the willingness of Asians to participate in CTs.
Conclusions
Our study results illustrate the current levels of awareness
and perception toward CTs in Korea and also clarify the
important factors that may predict a person’s willingness
to participate in CTs. These results indicate that an associ-
ation among awareness, perception toward CTs and will-
ingness to participate is a result of differential perception
on issues related to trust of CTs. A better understanding
of the perspectives of members of the general public who
are potential participants in a future CT would likely
improve recruitment. These findings might be helpful for
improving clinical researchers’ understanding about their
participants and useful when developing effective outreach
strategies for recruitment and retention for CTs.
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